Moderna stock faces earnings test after oncology gains

Moderna will report its third-quarter 2026 financial results before the market opens on Friday, November 6, as investors assess whether seasonal vaccine demand can support the company's recovery plan. The company announced the date and an 8:00 a.m. Eastern Time webcast in a Moderna press release carried by Lohud.

Vaccine sales meet pipeline expectations

The report will put Moderna's respiratory portfolio in focus, including its COVID-19 vaccines, influenza product mFlusiva and RSV vaccine mResvia. Investors will look for evidence that autumn demand can offset the company's dependence on COVID-related revenue and support management's full-year outlook.

The other major issue is oncology. Moderna and Merck are developing the personalized mRNA therapy intismeran autogene with Keytruda. Phase 3 melanoma data released in October showed a 42% reduction in the risk of recurrence or death compared with Keytruda alone. The result strengthens the strategic case for Moderna's move beyond respiratory vaccines, although regulatory approval, manufacturing and commercial execution remain ahead.

Friday report sets the next catalyst

Moderna's earnings call should provide the next detailed update on vaccine demand, research spending and the timing of potential regulatory submissions for intismeran. That information will help investors judge whether the oncology program is becoming a nearer-term commercial opportunity or remains primarily a long-term pipeline asset.

Moderna stock traded at 197.04 euros on Lang & Schwarz at 14:06 CET on Tuesday, November 3, 2026, 1.30 percent below the Xetra close of 199.64 euros on Monday, November 2, according to the De Belegger Xetra quote page. The movement leaves the November 6 report as the next scheduled company-specific catalyst.

Investors can follow the real-time quote of Moderna stock for subsequent trading updates.

The broader market context is available through S&P 500 market coverage.

For additional company developments, see More news and analyses on Moderna stock.